MT. KISCO, N.Y., Sept. 26, 2013 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) announced today that it has produced inventory for its new dietary supplement lines for sale; iNR Wellness™, iNR Wellness MD™, and iNR Strength™, with a retail value of over $1.25 million.
The products will be promoted through physician networks, fitness experts, online advertising, test-market television sponsorships, and social media. The products will be available to consumers through an online store this October and the campaigns will launch later this year.
Karen Kingston, Chief Marketing Officer, stated, "The iNR Wellness, iNR Wellness MD, and iNR Strength product lines have been custom formulated for consumers depending on their immune support needs. For example, iNR Strength is an ideal supplement for consumers who are more fitness goal oriented and will be represented by fitness experts and organizations. iNR Wellness MD is a clinically researched, doctor recommended supplement for consumers who may have weakened immune health due to illness or advancing age, and will be distributed through physician practices."
Mark McLaughlin, President & CEO, added, "ImmuDyne is particularly pleased with the progress we have made with private practice doctors and physician networks as they will be key partners in the launch of the iNR Wellness MD line. In addition, the launch of the iNR Wellness and iNR Strength products this fall provides the Company with a solid foundation to meet the 2014 revenue forecast put forth in our 18-month marketing plan. We can expand our manufacturing capabilities so that we can seamlessly produce additional product as market demand increases."
Ms. Kingston closed by emphasizing, "Part of our goal is to help consumers better understand immune health and how they can improve their energy level, biological responses, physical appearance, and even mood by supporting their immune system. Extensive clinical research has demonstrated that PURACERE™, the active ingredient in our new product lines, is a naturally powerful immunomodulator. The new iNR Wellness, iNR Wellness MD, and iNR Strength products can provide benefits to consumers regardless of the current state of their immune health."
iNR Wellness, iNR Wellness MD, and iNR Strength all contain the active ingredient PURACERE™. PURACERE is a proprietary, clinically researched, doctor-recommended, yeast beta 1,3/1,6-D-glucan. PURACERE is the purist yeast beta-glucan available. Unlike many other immune support dietary supplements, PURACERE does not contain any yeast by-products, endotoxins, excessive proteins, or ash. PURACERE has been clinically proven to prime the immune system and support immune health.
About ImmuDyne
ImmuDyne is a scientific-based, wellness company. Since 1990, ImmuDyne has been providing value to consumers with our extensively researched, ultrapure, proprietary yeast beta-1,3/1,6-D-glucan supplements. ImmuDyne has a portfolio of unique proprietary and patent-protected products with applications in the wellness, skin care, anti-aging, fitness, and health markets. ImmuDyne has offices located in Mt. Kisco, NY, Carlsbad, CA, and Florence, Kentucky. PURACERE, iNR Strength, iNR Wellness, and iNR Wellness MD are trademarks of ImmuDyne, Inc. 2013.
ImmuDyne shares trade under the ticker symbol IMMD and the Company can be found on the web at www.immudyne.com.
Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.